Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Life Technologies Corporation’s diagnostic testing menu is set to gain from the recent U.S. Food and Drug Administration's (FDA) 510(k) clearance for two infectious disease tests of the company’s partner Quidel Corporation (QDEL - Snapshot Report). According to both the companies, FDA recently allowed Quidel’s Molecular Influenza A+B assay and Molecular RSV + hMPV assay to run on QuantStudio Dx Real-Time PCR Instrument, Life Technologies’ flagship instrument for the diagnostics market.

Quidel’s Influenza A+B assay determines whether patients have the influenza A and/or B virus and detect the H7N9 subtype. According to the company, this subtype shows 30% mortality rate in China. Human exposure to infected poultry is the prime cause of transmission of H7N9 infections in human. However, recently the British Medical Journalreleased a probable case of human-to-human transmission of this infection.

On the other hand, Quidel's RSV + hMPV assay diagnoses two lung infections, respiratory syncytial virus (RSV) and human metapneumovirus (hMPV). hMPV accounts for 7.1% of respiratory tract infections. Thus, Life Technologies believes these clearances will help the company to expand its infectious disease detection menu, available on the QuantStudio Dx instrument.

Of late, Life Technologies has sharpened its focus on product platforms with a string of new product launches over the recent past. The disclosure of its impending acquisition by Thermo Fisher Scientific Inc. (TMO - Analyst Report) will further boost LIFE's product suite. With the overwhelming approval of its stockholders in favor of the deal, the impending acquisition of Life Technologies is now subject to customary closing conditions.

We are also encouraged by Life Technologies’ strategy to strengthen its presence in high-growth geographic markets such as Latin America, the Middle-East, China, and India. Life Technologies views immense potential in applied markets where technologies can help to carry out biological research in fast-growing industries such as forensics, and food and water testing.

Over the next few years, Life Technologies’ focus on developing industry-leading franchises in high-growth technology areas, applied markets and emerging geographies will be the key driver for long-term growth.

Currently, the LIFE stock carries a Zacks Rank #3 (Hold). On the other hand, Exactech Inc. (EXAC - Snapshot Report), carrying a Zacks Rank #2 (Buy) is worth considering.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
GENERAL FINA GFN 8.20 +5.67%
QIHOO 360 TE QIHU 91.57 +4.38%
VIPSHOP HOLD VIPS 140.01 +3.49%
INVESTMENT T ITG 19.16 +3.34%
VERTEX ENERG VTNR 7.38 +3.07%